| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Clinical practice guidelines for BRCA1 and BRCA2 genetic testing |
| Creator | Pujol et al. |
| Author | Pascal Pujol |
| Author | Massimo Barberis |
| Author | Philp Beer |
| Author | Eitan Friedman |
| Author | Josep M. Piulats |
| Author | Ettore D. Capoluongo |
| Author | Jesus Garcia Foncillas |
| Author | Isabelle Ray-Coquard |
| Author | Frédérique Penault-Llorca |
| Author | William D. Foulkes |
| Author | Clare Turnbull |
| Author | Helen Hanson |
| Author | Steven Narod |
| Author | Banu K. Arun |
| Author | Matti S. Aapro |
| Author | Jean-Louis Mandel |
| Author | Nicola Normanno |
| Author | Diether Lambrechts |
| Author | Ignace Vergote |
| Author | Michèle Anahory |
| Author | Bernard Baertschi |
| Author | Karen Baudry |
| Author | Yves-Jean Bignon |
| Author | Marc Bollet |
| Author | Carole Corsini |
| Author | Olivier Cussenot |
| Author | Marie Duboys de Labarre |
| Author | Florence Duchamp |
| Author | Clarisse Duriez |
| Author | Karim Fizazi |
| Author | Virginie Galibert |
| Author | Laurence Gladieff |
| Author | Joseph Gligorov |
| Author | Pascal Hammel |
| Author | Marion Imbert-Bouteille |
| Author | William Jacot |
| Author | Tatiana Kogut-Kubiak |
| Author | Pierre-Jean Lamy |
| Author | Sophie Nambot |
| Author | Yann Neuzillet |
| Author | Sylviane Olschwang |
| Author | Xavier Rebillard |
| Author | Jean-Marc Rey |
| Author | Chloé Rideau |
| Author | Jean-Philippe Spano |
| Author | Frédéric Thomas |
| Author | Isabelle Treilleux |
| Author | Marion Vandromme |
| Author | Julie Vendrell |
| Author | Michèle Vintraud |
| Author | Daniel Zarca |
| Author | Kevin S. Hughes |
| Author | Jose E. Alés Martínez |
| Abstract | BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing in clinical practice now overlap with both preventive and therapeutic management, updated and comprehensive practice guidelines for BRCA genotyping are needed. The integrative recommendations for BRCA testing presented here aim to (1) identify individuals who may benefit from genetic counselling and risk-reducing strategies; (2) update germline and tumour-testing indications for PARPi-approved therapies; (3) provide testing recommendations for personalised management of early and metastatic breast cancer; and (4) address the issues of rapid process and tumour analysis. An international group of experts, including geneticists, medical and surgical oncologists, pathologists, ethicists and patient representatives, was commissioned by the French Society of Predictive and Personalised Medicine (SFMPP). The group followed a methodology based on specific formal guidelines development, including (1) evaluating the likelihood of BRCAm from a combined systematic review of the literature, risk assessment models and expert quotations, and (2) therapeutic values of BRCAm status for PARPi therapy in BRCA-related cancer and for management of early and advanced breast cancer. These international guidelines may help clinicians comprehensively update and standardise BRCA testing practices. |
| Publication | European Journal of Cancer (Oxford, England: 1990) |
| Volume | 146 |
| Pages | 30-47 |
| Date | 2021-03 |
| Journal Abbr | Eur J Cancer |
| Language | eng |
| DOI | 10.1016/j.ejca.2020.12.023 |
| ISSN | 1879-0852 |
| Library Catalog | PubMed |
| Extra | PMID: 33578357 |
| Tags | BRCA-related cancer, BRCA1 and BRCA2 testing, BRCA1 Protein, BRCA2 Protein, Breast Neoplasms, Female, Genetic Testing, Germ-Line Mutation, Guidelines, Humans, marque, Ovarian Neoplasms, PARP inhibitors, Practice Guidelines as Topic, review |
| Date Added | 2022/07/29 - 15:54:24 |
| Date Modified | 2022/08/01 - 12:30:32 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
